Goldman Sachs upgraded GE HealthCare (GEHC) to Buy from Neutral with a price target of $100, up from $85. The firm’s confidence in the outlook for medical equipment spending in China has improved based on its “on-the-ground due diligence.” Over the course of 2025, GE HealthCare’s headwinds from China will replaced by tailwinds and should strengthen into 2026, the analyst tells investors in a research note. Goldman now sees GE Healthcare’s sales accelerating from 3.6% in 2025 to 5.5% in 2026 and sustained above 5% thereafter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare announces first patient doses of Flyrcado for CAD detection
- GE HealthCare management to hold a virtual meeting with BTIG
- GE Healthcare Earnings Call: Achievements and Challenges
- GE HealthCare price target raised to $103 from $96 at Wells Fargo
- Positive Outlook for GE Healthcare Technologies Inc.: Buy Rating Supported by Strong EPS Performance and Strategic Growth Initiatives